Notice of first launch, interruption or termination of supply of a human drug
 DateHolderCodeDrug ▼Date fromSubject
 17.3.2023G.L. Pharma GmbH (GLH-2)8712DAbiraterone G.L. Pharma 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.PVC/PVDC/Al))15.3.2023O
 13.3.2024G.L. Pharma GmbH (GLH-2)8712DAbiraterone G.L. Pharma 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.PVC/PVDC/Al))4.3.2024O
 6.7.2026G.L. Pharma GmbH (GLH-2)8712DAbiraterone G.L. Pharma 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.PVC/PVDC/Al))7.7.2026O
 30.6.2026G.L. Pharma GmbH (GLH-2)8712DAbiraterone G.L. Pharma 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.PVC/PVDC/Al))30.6.2026R
 15.2.2023G.L. Pharma GmbH (GLH-2)8712DAbiraterone G.L. Pharma 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.PVC/PVDC/Al))16.2.2023R
 18.1.2024G.L. Pharma GmbH (GLH-2)8712DAbiraterone G.L. Pharma 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.PVC/PVDC/Al))18.1.2024R
 9.5.2023medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)8030DAbiraterone medac 500 mg filmom obalené tablety (tbl flm 56x500 mg (blis.PVC/PVDC/Al))11.5.2023U
 28.1.2026medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)8030DAbiraterone medac 500 mg filmom obalené tablety (tbl flm 56x500 mg (blis.PVC/PVDC/Al))28.2.2026Z
 6.9.2024Mylan Ireland Limited (MNY)8549DAbiraterone Mylan 500 mg filmom obalené tablety (tbl flm 60x500 mg (blis.Al/PVC/PE/PVDC))30.11.2024Z
 3.3.2023Pharmevid s.r.o. (PEV)1420EAbiraterone Pharmevid 250 mg tablety (tbl 120x250 mg (fľ.HDPE))8.3.2023U
 7.11.2022Vipharm S.A. (VIH-PL-1)8608DAbiraterone Vipharm 500 mg (tbl flm 60x500 mg (blis.PVC/PVDC/Al))8.11.2022U
 27.9.2022Zentiva, k.s. (ZNT-1)9158DAbiraterone Zentiva (tbl flm 60x500 mg (blis.PVC/PVDC/Al))27.9.2022U
 13.11.2024Glenmark Pharmaceuticals s.r.o. (GLM-CZ)4283EAbisax 20 mg (tbl 30x20 mg (blis.Al/Al))14.11.2024U
 26.9.2024Glenmark Pharmaceuticals s.r.o. (GLM-CZ)4285EAbisax 20 mg (tbl 50x20 mg (blis.Al/Al))26.9.2024U
 23.1.2022Bristol-Myers Squibb Pharma EEIG (BMS-IE)47858Abraxane 5 mg/ml prášok na infúznu suspenziu (plv ins 1x100 mg (liek.inj.skl.))28.11.2021R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)